Trial Profile
Investigation for efficacy and safety of tau PET ligand [18F]PM-PBB3
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2020
Price :
$35
*
At a glance
- Drugs Florzolotau (Primary)
- Indications Alzheimer's disease; Corticobasal degeneration; Mild cognitive impairment; Progressive supranuclear palsy
- Focus Pharmacokinetics
- 29 May 2020 Status changed from recruiting to completed.
- 22 Jan 2018 New trial record